Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $21 Price Target

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.

HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $21 price target.

Read at benzinga.com